This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Clinical Usefulness

Dennis B. Smith, MD; G. Franklin Carl, PhD

Arch Neurol. 1982;39(6):363-366.

Abstract
• The need for rapid and accurate antiepileptic drug measurement in blood is well established. A substrate-labeled fluorescent immunoassay (FIA) has been developed that can measure phenobarbital, phenytoin, primidone, and carbamazepine in serum. To our knowledge, the primidone and carbamazepine assays have not previously been tested in a field trial. We compared FIA and the wellestablished antiepileptic drug immunoassay technique EMIT for the quantitation of both carbamazepine and primidone. In our hands, the FIA method compared favorably with the EMIT method for accuracy and reliability but is somewhat more time consuming. This method has the advantage of being more sensitive, however, and requires only a finger-stick blood sample. Because of this and the simplicity of the equipment required, the FIA system should also be relatively inexpensive to set up and to operate.

Author Affiliations
From the Department of Neurology, Medical College of Georgia, and the Veterans Administration Medical Center, Augusta.

Footnotes
Accepted for publication Sept 11, 1981.

Reprint requests to Neurology Research (151), Veterans Administration Medical Center, Downtown Division, Augusta, GA 30910 (Dr Carl).